Solicitation of Nominations for Appointment to the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 29335-29336 [2024-08447]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 78 / Monday, April 22, 2024 / Notices
protection through Executive Order,
statute, or regulation by Federal, State,
or local government, or a federally
recognized Indian Tribe. An action may
be categorically excluded if, although
sensitive resources are present, the
action would not have the potential to
cause significant impacts on those
resources (such as construction of a
building with its foundation well above
a sole-source aquifer or upland surface
soil removal on a site that has
wetlands). Environmentally sensitive
resources include, but are not limited to:
(i) Property (such as sites, buildings,
structures, and objects) of historic,
archeological, or architectural
significance designated by a Federal,
State, or local government, federally
recognized Indian Tribe, or Native
Hawaiian organization, or property
determined to be eligible for listing on
the National Register of Historic Places;
(ii) Federally listed threatened or
endangered species or their habitat
(including critical habitat) or federally
proposed or candidate species or their
habitat (Endangered Species Act); Statelisted or State-proposed endangered or
threatened species or their habitat;
federally protected marine mammals
and Essential Fish Habitat (Marine
Mammal Protection Act; MagnusonStevens Fishery Conservation and
Management Act); and otherwise
federally protected species (such as the
Bald and Golden Eagle Protection Act or
the Migratory Bird Treaty Act);
(iii) Floodplains and wetlands;
(iv) Areas having a special
designation such as federally and Statedesignated wilderness areas, national
parks, national monuments, national
natural landmarks, wild and scenic
rivers, State and Federal wildlife
refuges, scenic areas (such as National
Scenic and Historic Trails or National
Scenic Areas), and marine sanctuaries;
(v) Prime or unique farmland, or other
farmland of Statewide or local
importance, as defined at 7 CFR
658.2(a), ‘‘Farmland Protection Policy
Act: Definitions,’’ or its successor;
(vi) Special sources of water (such as
sole-source aquifers, wellhead
protection areas, and other water
sources that are vital in a region); and
(vii) Tundra, coral reefs, or rain
forests; or
(5) Involve genetically engineered
organisms, synthetic biology,
governmentally designated noxious
weeds, or invasive species, unless the
proposed activity would be contained or
confined in a manner designed and
operated to prevent unauthorized
release into the environment and
conducted in accordance with
applicable requirements, such as those
VerDate Sep<11>2014
06:41 Apr 20, 2024
Jkt 262001
of the Department of Agriculture, the
Environmental Protection Agency, and
the National Institutes of Health.
Proposed GSA Category of Actions
DOE’s electric vehicle charging
stations CATEX allows for the
installation, modification, operation,
and removal of electric vehicle charging
stations. GSA intends to apply this
CATEX to electric vehicle charging
station projects undertaken directly by
GSA, to electric vehicle charging station
actions requiring an approval by GSA,
or to electric vehicle charging station
projects financed in whole or in part
through Federal funds made available
by GSA.
GSA will consider each proposal for
electric vehicle charging stations to
ensure that the proposal is within the
scope of the CATEX. GSA intends to
apply this CATEX in a manner
consistent with DOE’s application to the
same types of proposals.
• Consideration of Extraordinary
Circumstances
When applying this CATEX, GSA will
evaluate the proposed action to ensure
evaluation of integral elements listed
above. In addition, in considering
extraordinary circumstances, GSA will
consider whether the proposed action
has the potential to result in significant
effects as described in DOE’s
extraordinary circumstances listed at 10
CFR 1021.410(b)(2). DOE defines
extraordinary circumstances as unique
situations presented by specific
proposals, including, but not limited to,
scientific controversy about the
environmental effects of the proposal;
uncertain effects or effects involving
unique or unknown risks; and
unresolved conflicts concerning
alternative uses of available resources.
• Consultation With DOE and
Determination of Appropriateness
GSA and DOE consulted on the
appropriateness of GSA’s adoption of
the CATEX in January 2024. This
consultation included a review of DOE’s
experience developing and applying the
CATEX, as well as the types of actions
for which GSA plans to utilize the
CATEX. Based on this consultation and
review, GSA has determined that the
types of projects it intends to undertake
to install, operate, modify, or remove
electric vehicle charging stations are
substantially similar to such projects for
which DOE has applied the CATEX.
Accordingly, the impacts of GSA
projects will be very similar to the
impacts of DOE projects, which are not
significant, absent the existence of
extraordinary circumstances that could
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
29335
involve potentially significant impacts.
Therefore, GSA has determined that its
proposed use of the electric vehicle
charging stations CATEX as described in
this notice would be appropriate.
• Notice to the Public and
Documentation of Adoption
This notice serves to identify to the
public and document GSA’s adoption of
DOE’s CATEX for electric vehicle
charging stations. The notice also
identifies the types of actions to which
GSA will apply the CATEX, as well as
the considerations that GSA will use in
determining whether an action is within
the scope of the CATEX. Upon issuance
of this notice, the adopted electric
vehicle charging stations CATEX will be
available to GSA.
Elliot Doomes,
Commissioner, Public Buildings Service, U.S.
General Services Administration.
[FR Doc. 2024–08505 Filed 4–19–24; 8:45 am]
BILLING CODE 6820–EY–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the CDC/HRSA
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), within the
Department of Health and Human
Services (HHS), is seeking nominations
for membership on the CDC/HRSA
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment (CHAC). CHAC consists of 18
experts in fields associated with public
health; epidemiology; laboratory
practice; immunology; infectious
diseases; substance use disorder;
behavioral science; health education;
healthcare delivery; state health
programs; clinical care; preventive
health; medical education; health
services and clinical research; health
equity; and healthcare financing, who
are selected by the Secretary, HHS.
DATES: Nominations for membership on
CHAC must be received no later than
October 1, 2024. Packages received after
SUMMARY:
E:\FR\FM\22APN1.SGM
22APN1
lotter on DSK11XQN23PROD with NOTICES1
29336
Federal Register / Vol. 89, No. 78 / Monday, April 22, 2024 / Notices
this time will not be considered for the
current membership cycle.
ADDRESSES: All nominations should be
emailed to nchhstppolicy@cdc.gov with
the subject line ‘‘CHAC 2025
Nomination.’’
FOR FURTHER INFORMATION CONTACT:
Marah Condit, M.S., Committee
Management Lead, Office of Policy,
Planning, and Partnerships, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop US8–6, Atlanta,
Georgia 30329–4027. Telephone: (404)
639–3423; Email: nchhstppolicy@
cdc.gov.
SUPPLEMENTARY INFORMATION: The
Secretary, Department of Health and
Human Services (HHS), and by
delegation, the Director, Centers for
Disease Control and Prevention (CDC),
and the Administrator, Health
Resources and Services Administration
(HRSA), are authorized by the Public
Health Service Act to: (1) conduct,
encourage, cooperate with, and assist
other appropriate public health
authorities, scientific institutions, and
scientists in the conduct of research,
investigations, experiments,
demonstrations, and studies relating to
the causes, diagnosis, treatment, control,
and prevention of physical and mental
diseases and other impairments; (2)
assist states and their political
subdivisions in preventing, suppressing,
and treating communicable diseases and
other preventable conditions and in
promoting health and well-being; (3)
assist public and non-profit private
entities in preventing, controlling and
treating sexually transmitted diseases
(STDs), including the human
immunodeficiency virus (HIV); (4)
improve health and achieve health
equity through access to quality services
and a skilled health workforce and
innovative programs; (5) support
healthcare services to persons with or
who experience risk for HIV, viral
hepatitis, and other STDs; (6) advance
the education of health professionals
and the public about HIV, viral
hepatitis, and other STDs; and (7)
improve adolescent and school health as
it pertains to HIV, viral hepatitis, and
STDs.
The CDC/HRSA Advisory Committee
on HIV, Viral Hepatitis and STD
Prevention and Treatment (CHAC)
meets at least two times each calendar
year, or at the discretion of the
Designated Federal Officers in
consultation with the CHAC co-chairs.
HHS policy stipulates that committee
membership be balanced in terms of
points of view represented and the
VerDate Sep<11>2014
06:41 Apr 20, 2024
Jkt 262001
committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on Federal workgroups or
prior experience serving on a Federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships. The CHAC
charter stipulates that the Committee
must include at least four members who
are persons with HIV. The Committee
may also include representation from
persons with lived experience, such as
those who have experienced viral
hepatitis, STDs, and drug use; state and
local health and education agencies;
HIV/viral hepatitis/STD communitybased organizations; and the ethics or
faith-based community.
Committee members are Special
Government Employees, requiring the
filing of financial disclosure reports at
the beginning of and annually during
their terms. Individuals who are
selected for appointment will be
required to provide detailed information
regarding their financial interests and,
for example, any work they do for the
federal government through research
grants or contracts. Disclosure of this
information is required in order for CDC
ethics officials to determine whether
there is a conflict between the SGE’s
public duties as a member of CHAC and
the SGE’s private interests, including an
appearance of a loss of impartiality as
defined by Federal laws and regulations,
and to identify any required remedial
action needed to address the potential
conflict.
CDC and HRSA review potential
candidates for CHAC membership when
a vacancy arises and provide a slate of
nominees for consideration to the
Secretary of HHS for final selection.
CDC and HRSA each publish a Federal
Register notice and will be using a joint
process to nominate nominees on a
rolling basis; thus, applications received
by CDC will be shared with HRSA for
consideration. Therefore, potential
candidates need only apply in response
to one of the Federal Register notices.
HHS notifies selected candidates of
their appointment near the start of the
term in December 2025, or as soon as
the HHS selection process is completed.
Note that the need for different expertise
varies from year to year and a candidate
who is not selected in one year may be
reconsidered in a subsequent year.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Candidates should submit the
following items:
D A letter of interest or personal
statement from the nominee stating how
the nominee’s expertise would inform
the work of CHAC
D A biographical sketch of the
nominee (500 words or fewer)
D Current curriculum vitae or resume,
including complete contact information
(telephone numbers, mailing address,
and email address)
D At least one letter of
recommendation from person(s) not
employed by HHS. Candidates may
submit letter(s) from current HHS
employees if they wish, but at least one
letter must be submitted by a person not
employed by an HHS agency (e.g., CDC,
National Institutes of Health, Food and
Drug Administration).
Nominations may be submitted by the
candidate or by the person/organization
recommending the candidate. CDC and
HRSA will collect and retain
nominations received for up to two
years to create a pool of potential CHAC
nominees. When a vacancy occurs, CDC
and HRSA will review nominations and
may contact nominees at that time.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–08447 Filed 4–19–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Board of Scientific
Counselors, Office of Readiness and
Response
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
SUMMARY:
E:\FR\FM\22APN1.SGM
22APN1
]]>Agencies
[Federal Register Volume 89, Number 78 (Monday, April 22, 2024)]
[Notices]
[Pages 29335-29336]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08447]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Appointment to the CDC/HRSA
Advisory Committee on HIV, Viral Hepatitis and STD Prevention and
Treatment
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), within the Department
of Health and Human Services (HHS), is seeking nominations for
membership on the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis
and STD Prevention and Treatment (CHAC). CHAC consists of 18 experts in
fields associated with public health; epidemiology; laboratory
practice; immunology; infectious diseases; substance use disorder;
behavioral science; health education; healthcare delivery; state health
programs; clinical care; preventive health; medical education; health
services and clinical research; health equity; and healthcare
financing, who are selected by the Secretary, HHS.
DATES: Nominations for membership on CHAC must be received no later
than October 1, 2024. Packages received after
[[Page 29336]]
this time will not be considered for the current membership cycle.
ADDRESSES: All nominations should be emailed to [email protected]
with the subject line ``CHAC 2025 Nomination.''
FOR FURTHER INFORMATION CONTACT: Marah Condit, M.S., Committee
Management Lead, Office of Policy, Planning, and Partnerships, National
Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US8-6,
Atlanta, Georgia 30329-4027. Telephone: (404) 639-3423; Email:
[email protected].
SUPPLEMENTARY INFORMATION: The Secretary, Department of Health and
Human Services (HHS), and by delegation, the Director, Centers for
Disease Control and Prevention (CDC), and the Administrator, Health
Resources and Services Administration (HRSA), are authorized by the
Public Health Service Act to: (1) conduct, encourage, cooperate with,
and assist other appropriate public health authorities, scientific
institutions, and scientists in the conduct of research,
investigations, experiments, demonstrations, and studies relating to
the causes, diagnosis, treatment, control, and prevention of physical
and mental diseases and other impairments; (2) assist states and their
political subdivisions in preventing, suppressing, and treating
communicable diseases and other preventable conditions and in promoting
health and well-being; (3) assist public and non-profit private
entities in preventing, controlling and treating sexually transmitted
diseases (STDs), including the human immunodeficiency virus (HIV); (4)
improve health and achieve health equity through access to quality
services and a skilled health workforce and innovative programs; (5)
support healthcare services to persons with or who experience risk for
HIV, viral hepatitis, and other STDs; (6) advance the education of
health professionals and the public about HIV, viral hepatitis, and
other STDs; and (7) improve adolescent and school health as it pertains
to HIV, viral hepatitis, and STDs.
The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment (CHAC) meets at least two times each calendar
year, or at the discretion of the Designated Federal Officers in
consultation with the CHAC co-chairs.
HHS policy stipulates that committee membership be balanced in
terms of points of view represented and the committee's function.
Appointments shall be made without discrimination on the basis of age,
race, ethnicity, gender, sexual orientation, gender identity, HIV
status, disability, and cultural, religious, or socioeconomic status.
Nominees must be U.S. citizens and cannot be full-time employees of the
U.S. Government. Current participation on Federal workgroups or prior
experience serving on a Federal advisory committee does not disqualify
a candidate; however, HHS policy is to avoid excessive individual
service on advisory committees and multiple committee memberships. The
CHAC charter stipulates that the Committee must include at least four
members who are persons with HIV. The Committee may also include
representation from persons with lived experience, such as those who
have experienced viral hepatitis, STDs, and drug use; state and local
health and education agencies; HIV/viral hepatitis/STD community-based
organizations; and the ethics or faith-based community.
Committee members are Special Government Employees, requiring the
filing of financial disclosure reports at the beginning of and annually
during their terms. Individuals who are selected for appointment will
be required to provide detailed information regarding their financial
interests and, for example, any work they do for the federal government
through research grants or contracts. Disclosure of this information is
required in order for CDC ethics officials to determine whether there
is a conflict between the SGE's public duties as a member of CHAC and
the SGE's private interests, including an appearance of a loss of
impartiality as defined by Federal laws and regulations, and to
identify any required remedial action needed to address the potential
conflict.
CDC and HRSA review potential candidates for CHAC membership when a
vacancy arises and provide a slate of nominees for consideration to the
Secretary of HHS for final selection. CDC and HRSA each publish a
Federal Register notice and will be using a joint process to nominate
nominees on a rolling basis; thus, applications received by CDC will be
shared with HRSA for consideration. Therefore, potential candidates
need only apply in response to one of the Federal Register notices. HHS
notifies selected candidates of their appointment near the start of the
term in December 2025, or as soon as the HHS selection process is
completed. Note that the need for different expertise varies from year
to year and a candidate who is not selected in one year may be
reconsidered in a subsequent year.
Candidates should submit the following items:
[ssquf] A letter of interest or personal statement from the nominee
stating how the nominee's expertise would inform the work of CHAC
[ssquf] A biographical sketch of the nominee (500 words or fewer)
[ssquf] Current curriculum vitae or resume, including complete
contact information (telephone numbers, mailing address, and email
address)
[ssquf] At least one letter of recommendation from person(s) not
employed by HHS. Candidates may submit letter(s) from current HHS
employees if they wish, but at least one letter must be submitted by a
person not employed by an HHS agency (e.g., CDC, National Institutes of
Health, Food and Drug Administration).
Nominations may be submitted by the candidate or by the person/
organization recommending the candidate. CDC and HRSA will collect and
retain nominations received for up to two years to create a pool of
potential CHAC nominees. When a vacancy occurs, CDC and HRSA will
review nominations and may contact nominees at that time.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-08447 Filed 4-19-24; 8:45 am]
BILLING CODE 4163-18-P
